ArticleBMJ public health2025
Disparities in cancer incidence, stage at diagnosis, treatment and mortality across socioeconomic groups in Finland: a register-based population study.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland.Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Socioeconomic inequalities in various cancer-related indicators exist globally, but the evidence is fragmented even within countries. We aim to assess disparities in cancer incidence, stage at diagnosis, treatment and mortality by socioeconomic status (SES, measured as education and income) in Finland across the entire cancer journey. Methods: Among the total Finnish population aged 30+ years, we identified those newly diagnosed with cancer between 2000-2019 based on Finnish Population Register and Cancer Register data. We calculated standardised rate ratios (SRRs) to compare incidence between SES groups. We used logistic regression models to estimate OR of being diagnosed with later stage cancer and of receiving specific treatments, and Cox models to estimate HR of mortality across SES groups. Findings: Among 4 536 724 Finnish residents, 240 746 men and 228 776 women were newly diagnosed with cancer between 2000 and 2019. Systematic disparities were observed for incidence, stage at diagnosis, treatment and mortality for all cancers and for most types of cancers. Among both men (SRR 1.17, 95% CI 1.16 to 1.19) and women (SRR 1.05, 95% CI 1.04 to 1.06), those with lower education had higher total cancer incidence rates than those with higher education. Patients with lower education had higher odds of being diagnosed with stage IV cancer than patients with higher education (men: OR 1.10, 95% CI 1.08 to 1.12; women: OR 1.15, 95% CI 1.13 to 1.17). Both male and female patients with lower education had a lower likelihood of being treated with surgery, chemotherapy and radiation than patients with higher education. Finally, patients with lower education had higher mortality rates than patients with higher education (men: HR 1.13, 95% CI 1.10 to 1.16; women: HR 1.14, 95% CI 1.11 to 1.17). Similar patterns were observed by income. Conclusions: Low SES individuals were disadvantaged in all aspects of their cancer journey for total cancer and most cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.